Sight Sciences reported Q3 2025 financial results and raised full-year revenue guidance today, and announced the appointments of a new COO and CFO.
Friday, November 7, 2025
Inflammation biotech Evommune heads to NYSE with $150M IPO
Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO the inflammation biotech will use to fund a pair of clinical-stage candidates.
The Palo Alto, California-based company is offering 9.3 million shares at $16 apiece—falling in the middle of the $15-$17 range the biotech outlined last week.
This is set to bring in gross proceeds of $150 million, according to Evommune, although this could be boosted by about $22.5 million if underwriters take up their 30-day option to pick up an additional 1.4 million share sat the same price.
The shares are due to start trading on the NYSE this morning under the ticker “EVMN.”
Amid the government shutdown, Evommune had said that it expected to complete the IPO pricing using Section 8(a) of the Securities Act, which allows for a registration to become effective after a 20-day waiting period.
The company has previously laid out how it will use the financing to fuel ongoing development of two clinical-stage assets, both of which are currently being tested in phase 2 studies.One of those programs is EVO756, which the biotech is developing for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). The asset is an oral small-molecule antagonist of MRGPRX2, a receptor usually found on mast cells and peripheral sensory neurons. Top-line data from a phase 2b trial in AD are expected in the second half of 2026.
Recently, Evommune shared full data from a separate phase 2 study of EVO756 in 30 adults with CSU, pointing to clinical responses observed in 93% of patients at four weeks.
Evommune’s IPO comes hot on the heels of MapLight Therapeutics, which went public with a $250 million Nasdaq debut last week. It remains to be seen whether more biotechs will follow their lead, as public and private markets more broadly begin to show signs of recovery.
https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-heads-nyse-150m-ipo
Organogenesis Applauds CMS’s Significant Step In Payment Reform
Organogenesis (Nasdaq: ORGO) applauded CMS’s finalization of payment reform for skin substitutes/CTPs under the CY 2026 Physician Fee Schedule announced Nov. 3, 2025.
The company highlighted that CMS finalized FDA classifications and a per centimeter-square payment methodology for both physician office and hospital outpatient settings, and said CMS recognized the clinical differentiation of PMA products, which the company believes will increase access and support higher payment and expanded access for PMA technologies. Organogenesis reiterated its multi-decade leadership and said its evidence-based portfolio positions it well for the skin substitutes market in 2026 and beyond.
The release contains forward-looking statements and cautions that actual outcomes are subject to risks and uncertainties described in the company’s SEC filings.
Subscribe to:
Comments (Atom)